The SP142 PD-L1 antibody is the accompanying diagnostic assay for the PD-L1 inhibitor atezolizumab, which was first reported effective in combination with nab-paclitaxel in patients with unresectable, locally advanced, or metastatic triple-negative breast cancer in the phase 3 IMpassion130 trial39. The gene discussed is CD274; the disease is triple-negative breast carcinoma.